Antitumor efficacy of a neoantigen cancer vaccine delivered by electroporation is influenced by microbiota composition. (1st January 2021)

• Record Type: Journal Article
• Authors: Lione, Lucia; Salvatori, Erika; Petrazzuolo, Adriana; Massacci, Alice; Maggio, Roberta; Conforti, Antonella; Compagnone, Mirco; Aurisicchio, Luigi; Ciliberto, Gennaro; Palombo, Fabio
• Is Part Of: Oncoimmunology. Volume 10:Number 1(2021)
• Publication Date: 2021-01-01
• Subjects: Microbiota -- neoantigens -- vaccine -- T cells; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2021.1898832
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Cancer is a heterogeneous disease and its treatment remains unsatisfactory with inconstant therapeutic responses. This variability could be related, at least in part, to different and highly personalized gut microbiota compositions. Different studies have shown an impact of microbiota on antitumor therapy. It has been demonstrated that some gut bacteria influences the development and differentiation of immune cells, suggesting that different microbiota compositions could affect the efficacy of the antitumor vaccine. Emerging data suggest that recognition of neoantigens for the generation of neoantigen cancer vaccines (NCVs) could have a key role in the activity of clinical immunotherapies. However, it is still unknown whether there is a crosstalk between microbiota and NCV. This study aimed to understand the possible mechanisms of interaction between gut microbiota and NCV delivered by DNA-electroporation (DNA-EP). We found that decreased microbiota diversity induced by prolonged antibiotic (ATB) treatment is associated with higher intratumor specific immune responses and consequently to a better antitumor effect induced by NCV delivered by DNA-EP.